Pulmonx (LUNG) Projected to Release Earnings on Tuesday

Pulmonx (NASDAQ:LUNG) is expected to release its Q3 2026 results after the market closes on Tuesday, October 27th. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $21.93 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 4:30 PM ET.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.04. Pulmonx had a negative return on equity of 96.66% and a negative net margin of 55.03%. The business had revenue of $22.76 million for the quarter, compared to analyst estimates of $22.39 million. On average, analysts expect Pulmonx to post ($1.05) EPS for the current fiscal year and ($0.94) EPS for the next fiscal year.

Pulmonx Price Performance

Shares of NASDAQ:LUNG opened at $1.83 on Monday. The company has a debt-to-equity ratio of 0.95, a quick ratio of 3.52 and a current ratio of 4.32. Pulmonx has a 1 year low of $1.13 and a 1 year high of $2.89. The stock has a market capitalization of $78.60 million, a P/E ratio of -1.58 and a beta of 0.33. The stock has a 50-day simple moving average of $2.03 and a 200-day simple moving average of $1.67.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Pulmonx from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 25th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Pulmonx presently has an average rating of “Moderate Buy” and an average price target of $7.67.

Insider Activity at Pulmonx

In related news, insider Srikanth Radhakrishnan sold 14,245 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $2.26, for a total value of $32,193.70. Following the completion of the sale, the insider directly owned 316,994 shares in the company, valued at approximately $716,406.44. This represents a 4.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel David Lehman sold 14,334 shares of the stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $2.26, for a total value of $32,394.84. Following the completion of the sale, the general counsel owned 361,827 shares of the company’s stock, valued at approximately $817,729.02. This represents a 3.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 78,340 shares of company stock worth $177,048. 7.50% of the stock is currently owned by corporate insiders.

Pulmonx Company Profile

Pulmonx Corporation is a medical device company focused on developing minimally invasive treatments for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company’s technologies are designed to reduce hyperinflation in damaged portions of the lung and help improve breathing, exercise capacity and quality of life.

Pulmonx’s primary product is the Zephyr Endobronchial Valve, a bronchoscopically implanted, one-way valve intended for certain patients with severe emphysema.